A proof of concept study showed that the SGLT2 inhibitor empagliflozin when added to insulin therapy improved glycemic control in type 1 diabetic subjects while lowering the insulin dose and body weight as well as the frequency of hypoglycemia [2]. This evidence concerns the gene INS and Hypoglycemia.